Business Description
Cantargia AB
ISIN : SE0006371126
Compare
Compare
Traded in other countries / regions
CANTA.Sweden7V3.GermanyCANTAs.UK IPO Date
2019-09-02Description
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.74 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | -1.4 | |||||
| 3-Year FCF Growth Rate | -3.1 | |||||
| 3-Year Book Growth Rate | -50.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 18.76 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.67 | |||||
| Quick Ratio | 3.67 | |||||
| Cash Ratio | 3.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -136.3 | |||||
| ROA % | -103.86 | |||||
| ROIC % | -634.6 | |||||
| 3-Year ROIIC % | -1255.48 | |||||
| ROC (Joel Greenblatt) % | -4698.46 | |||||
| ROCE % | -135.99 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.89 | |||||
| Price-to-Tangible-Book | 4.09 | |||||
| EV-to-EBIT | -1.09 | |||||
| EV-to-EBITDA | -1.11 | |||||
| EV-to-Forward-EBITDA | -1.14 | |||||
| EV-to-FCF | -1.06 | |||||
| Price-to-Net-Current-Asset-Value | 4.26 | |||||
| Price-to-Net-Cash | 4.8 | |||||
| Earnings Yield (Greenblatt) % | -91.74 | |||||
| FCF Yield % | -66.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cantargia AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.3 | ||
| Beta | 4.28 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 4.174 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 4.174 - 4.174 | ||
| Shares Outstanding (Mil) | 183.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cantargia AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cantargia AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cantargia AB Frequently Asked Questions
What is Cantargia AB(CHIX:CANTAs)'s stock price today?
The current price of CHIX:CANTAs is kr4.17. The 52 week high of CHIX:CANTAs is kr4.17 and 52 week low is kr4.17.
When is next earnings date of Cantargia AB(CHIX:CANTAs)?
The next earnings date of Cantargia AB(CHIX:CANTAs) is 2024-11-15.
Does Cantargia AB(CHIX:CANTAs) pay dividends? If so, how much?
Cantargia AB(CHIX:CANTAs) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers